Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing ...

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab. A study on the efficacy of the biologic drug, dupilumab, found ...

The American College of Pulmonologists has published new clinical guidelines for the use of biological therapy in severe ...

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Dr. Marc Cromie with the Chattanooga Allergy Clinic joins News 12’s Chip Chapman at the start of the New Year with some health tips.  CHATTANOOGA, Tenn. (WDEF) – Flu season is here but best not to ...

Treatment with twice-yearly depemokimab resulted in a significant reduction in the rate of annualized asthma exacerbations compared with placebo. The Food and Drug Administration (FDA) has approved ...

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as an add-on maintenance treatment of severe asthma with an eosinophilic ...

Please provide your email address to receive an email when new articles are posted on . Mucus scores included 6 for the nonbiologic group and 3 for the biologic group. Mucus scores also included 5 for ...

A landmark study has shown that severe asthma can be controlled using biologic therapies, without the addition of regular high-dose inhaled steroids which can have significant side effects. The ...

Unlocking the Secrets of Severe Asthma: From Pathways to Precision is the launch of the brand new reelCE™ initiative, designed to educate U.S.-based pulmonologists, allergists, nurse practitioners, ...

LONDON (Reuters) - AstraZeneca hopes to convince doctors its experimental injection for severe asthma has an edge over two approved rivals after clinical trials data on Monday showed it worked well ...